



Att. Docket No.: REG 910A

THE UNITED STATES PATENT AND TRADEMARK OFFICE

USN : 10/086,201

Applicant: Glass, David

Date Filed: February 28, 2002

Title: Methods of Identifying Agents
Affecting Atrophy and Hypertrophy

Examiner: Not Yet Known

Group: 1623

1623
#4
RECEIVED
FEB 14 2003
TECH CENTER 1600/2900

FIRST CLASS MAIL CERTIFICATE

I hereby certify that this document is being deposited with the United States Postal Service on this date as first class mail addressed to: Commissioner for Patents, United States Patent and Trademark Office, Washington, D.C. 20231.

Bernadette B. Fahey
Bernadette B. Fahey

February 6, 2003
Date

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 and 1.97**

Assistant Comm. Patent and Trademarks
Washington, D.C. 20231

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449 and copies of references listed therein. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:

- ☒ (b) Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

or

☐ (c) After (b) above, but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or any action that otherwise closes prosecution in the application. Accordingly, the undersigned certifies as follows:

☐ (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

☐ (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

or

☐ This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p);

or

☐ (d) After (c) above, but on or before payment of the issue fee and the undersigned certifies as follows:

☐ (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

☐ (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

and

☐ This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p).


REQUEST FOR TRANSFER OF REFERENCE COPIES

[] Applicants respectfully request that the cited references filed in the Information Disclosure Statement submitted in connection with parent application USSN _____, filed _____, be transferred to the subject application for consideration by the Examiner

Fees

The fee required for the filing of this Information Disclosure Statement is estimated to be \$ _____. Applicants hereby authorize such charge to Deposit Account number 18-0650. If any additional fee should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-050.

Respectfully submitted



Laura J. Fischer

Reg. No. 50,420

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591

(914) 345-7400



FORM PTO-1449

Att. Docket No.: REG 910A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Patent No.: 10/086,201

Applicant: Glass, David

Date Filed: 2/28/02

Title: Methods of Identifying Agents Affecting
Atrophy and Hypertrophy

Examiner: Not Yet Known

Group Art Unit: 1643

February 6, 2003

RECEIVED
FEB 14 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Publication Number	Publication Date	Name
----------------------	------------------	---------------	-----------------------	---------------------	------

____ US 6,025,198A (Bennett et al) 15 February 2000

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Date	Class/ Subclass	Translation Yes No
----------------------	--------------------	------	---------	------	--------------------	-----------------------

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

____ Aman, M. J., Lamkin, T. D., Okada, H., Kurosaki, T. & Ravichandran, K. S. J. *Biol. Chem.*
273,33922-33928 (1998)

____ Brunn, G. J. *et al. Science* 277, 99-101 (1997)

____ Coleman ME, DeMayo F, Yin KC, Lee HM, Geske R, Montgomery C, Schwartz R J *Biol Chem*
1995 May 19;270(20):12109-16

- _____ Friday, B. B., Horsley, V. & Pavlath, G. K. *J. Cell Biol.* **149**, 657-666 (2000)
- _____ Liu, Q. *et al. Genes Dev.* **13**, 786-791 (1999)
- _____ Musaro, A., McCullagh, K. J., Naya, F. J., Olson, E. N. & Rosenthal, N. *Nature* **400**, 581-585 (1999);
- _____ Rameh and Cantley (1999) *J. Biol. Chem.* **274**:8347
- _____ Rhoads, R. E. *J. Biol. Chem.* **274**, 30337-30340 (1999)
- _____ Rommel, C. *et al. Science* **286**, 1738-1741 (1999);
- _____ Toker and Cantley (1997) *Nature* **387**:673;
- _____ Database Medline on STN, IRIBHN, IBMM, rue des professeurs Jeener et Brachet 12 (Belgium),
Accession No, 2001310131, Clement et al, The lipid phosphatase SHIP2 controls insulin
sensitivity, abstract, *NATURE*, 04 January 2001, Vol 409(6816) Pages 92-97.

EXAMINER
CONSIDERED


DATE

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:


Laura J. Fischer
Reg. No. 50,420
Attorney for Applicants
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400